H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on Kyverna Therapeutics to $25 from $20 and keeps a Buy rating on the shares. Following a discussion with management, the firm added stiff person syndrome into Kyverna's model ahead of a 2027 miv-cel launch. It assigns a 70% probability of approval and $800M in peak sales.
